Cadrenal Therapeutics, Inc.
CVKDHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cadrenal Therapeutics, Inc. (CVKD) is listed under Biotechnology. At a $6.7M market cap, Cadrenal Therapeutics, Inc. ranks as a micro-cap company within healthcare. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.
Market Cap
$6.7M
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-0.70
EPS (TTM)
$-5.80
EPS (Fwd)
$-3.09
ROE
-300.6%
ROA
-139.2%
Cash
$2.3M
Total Debt
$0
Free CF
-$6.6M
52W Change
-79.9%
Annual Financials
Cash vs Debt
Where CVKD stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CVKD finished 59.87% below its 150-day moving average ($6.03) and 68.32% below its 200-day moving average ($7.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CVKD overbought or oversold?
At the July 15, 2026 close, CVKD's RSI(14) was 37.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cadrenal Therapeutics, Inc. reports $2.3M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$6.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -300.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.75 means CVKD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CVKD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.